Diarrhea

Results from a 2023 nationwide survey published in Gastroenterology estimated the prevalence of Rome IV irritable bowel syndrome in the U.S. climbing to 6.1% — higher than previous reports of 4.7% to 5.3%.

In this Healio video exclusive, Walker D. Redd, MD, discusses a study of patients with chronic diarrhea who underwent colonoscopy, which revealed 10% who had microscopic colitis “remained unaware” of their diagnosis 1 year after evaluation.

California hospitals detected a high incidence of Clostridioides difficile infection among outpatients treated for diarrhea despite a low rate of testing, suggesting that outpatient C. difficile may be underdiagnosed, researchers said.

Nearly 7.5 million Americans are expected to reach their holiday destinations by plane this year — a daunting task for most individuals but even more challenging for those with gastrointestinal disorders.

Acamprosate and oral naltrexone were associated with significantly improved alcohol consumption outcomes compared with placebo and could be used alongside psychosocial interventions as first-line treatment for alcohol use disorder.

In this video, Sun Y. Lee, MD, MSc, an associate professor at Boston University Chobanian and Avedisian School of Medicine, discusses her recent review of the literature regarding hyperthyroidism and its clinical management.

The FDA granted accelerated approval to entrectinib for infants aged 1 month and older who have solid tumors that harbor neurotrophic tyrosine receptor kinase, or NTRK, gene fusion for whom there are no effective treatments.

An acute gastroenteritis outbreak in late summer 2022 among hikers on the Pacific Crest Trail in Washington was likely caused by norovirus, according to a CDC investigation in Morbidity and Mortality Weekly Report.

A nationwide survey of nearly 89,000 individuals estimated the prevalence of Rome IV irritable bowel syndrome in the U.S. to be 6.1% compared with 4.7% to 5.3% in previous reports, according to a cross-sectional study in Gastroenterology.